This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
Diagnosed with recurrent/progressive glioblastoma.
Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
Patients with extracranial metastases.
Previously received treatment with oncolytic viruses, gene therapy.
Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
Subject is known to have an allergic reaction to any of the components of VRT106.